SAB Biotherapeutics Strengthens Leadership with New Board Appointments

MIAMI, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a progressive clinical-stage biopharmaceutical company, has made significant enhancements to its governance by appointing David Zaccardelli, Pharm.D. as Chair of the Board and Rita Jain, M.D. as an independent director. These appointments are effective immediately and position SABS for accelerated growth in developing its innovative therapies for autoimmune diseases, including type 1 diabetes (T1D).

Leadership Enhancements at SAB Biotherapeutics

CEO Samuel J. Reich expressed enthusiasm about the new appointments, stating, “We are excited to welcome Dr. David Zaccardelli and Dr. Rita Jain to our Board of Directors. I, along with the rest of our Board, am confident that David and Rita will make a significant impact on SAB BIO.”

Mr. Reich emphasized Dr. Zaccardelli’s extensive expertise in the biotech field, noting his pivotal role in the launch of Ohtuvayre®, recognized as one of the most successful biotech product launches in the last decade. The strategic decision to appoint Dr. Zaccardelli as Chair underscores SABS’s growth trajectory and validates its forward-looking approach to the market.

New Chair Dr. David Zaccardelli

Dr. Zaccardelli brings over 20 years of transformative experience in the biopharmaceutical sector. As he steps into his role, he stated, “I am pleased to join SAB BIO as Chair of the Board at this pivotal time for the Company. SAB-142 is a potential game changer for people living with T1D and an extraordinary opportunity to fundamentally change the treatment paradigm.” His leadership is expected to guide SAB in critical clinical development phases and potential commercial launch preparations.

Independent Director Dr. Rita Jain

Joining Dr. Zaccardelli is Dr. Rita Jain, a rheumatologist who has spent over two decades advancing drug development strategies across various therapeutic areas. Dr. Jain commented, “SAB BIO is at the forefront of developing a therapy that may dramatically transform the treatment of Type 1 Diabetes, and, in the future, the lives of people living with other autoimmune diseases.” Her expertise in navigating clinical trials will be essential for advancing SAB-142 into a registrational clinical trial.

About SAB Biotherapeutics

SAB Biotherapeutics (SABS) is committed to pioneering the development of multi-specific, high-potency human immunoglobulin G (hIgG) therapies for immune and autoimmune diseases. The flagship candidate, SAB-142, represents a promising disease-modifying approach targeting T1D with the potential to alter the disease’s treatment landscape.

Utilizing innovative genetic engineering techniques, SAB BIO has cultivated groundbreaking technology that allows for the creation of novel therapeutic candidates without relying on human donors or convalescent plasma. The biopharmaceutical company’s focus on developing transchromosomic cattle, or Tc-Bovine™, facilitates the production of high-potency hIgGs, which could address numerous critical unmet medical needs.

Looking Ahead: The Future of SABS

As SAB Biotherapeutics continues to advance its pivotal therapies, the integration of Dr. Zaccardelli and Dr. Jain into the Board marks a significant milestone in its strategic vision. Their combined experience and insight will be invaluable as the company seeks to enhance shareholder value and impact the lives of patients dealing with complex autoimmune conditions.